Latest News and Press Releases

Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026 Cash and Securities of $219.8 Million as of Year-End Supports Ongoing...

- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 -  - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene...

- New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history - - Data expand on previously reported results demonstrating that...

Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026 Budoprutug clinical trials ongoing in pMN, ITP, and SLE, with initial data from all three...

Phase 1 clinical trial of SL-325 ongoing, with data expected in the second quarter of 2026 –Phase 2 clinical trial of SL-325 in patients with Crohn’s disease expected to initiate in the third quarter...

CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies

- Planned submission for U.S. Accelerated Approval of z-rostudirsen on track for Q2 2026; potential launch in Q1 2027 - - Positive topline results reported from Phase 1/2 DELIVER trial of...

Entrada Therapeutics reports financial results for the fourth quarter and full year ended December 31, 2025, and highlights recent business updates.

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

VANCOUVER, British Columbia, Feb. 24, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com Market Intelligence Brief — WHAT'S HAPPENING: The infrastructure holding the global economy together is being...